Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.
IPO Year: 2021
Exchange: NASDAQ
Website: vaxxinity.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/8/2023 | $7.00 | Outperform | Robert W. Baird |
| 4/27/2022 | In-line | Evercore ISI | |
| 12/29/2021 | $18.00 | Buy | Jefferies |
| 12/7/2021 | $18.00 | Buy | Jefferies |
| 12/6/2021 | $21.00 | Buy | B of A Securities |
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
3 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
15-12G - Vaxxinity, Inc. (0001851657) (Filer)
DEF 14C - Vaxxinity, Inc. (0001851657) (Filer)
EFFECT - Vaxxinity, Inc. (0001851657) (Filer)
S-8 POS - Vaxxinity, Inc. (0001851657) (Filer)
S-8 POS - Vaxxinity, Inc. (0001851657) (Filer)
POS AM - Vaxxinity, Inc. (0001851657) (Filer)
10-K/A - Vaxxinity, Inc. (0001851657) (Filer)
PRE 14C - Vaxxinity, Inc. (0001851657) (Filer)
25 - Vaxxinity, Inc. (0001851657) (Filer)
8-K - Vaxxinity, Inc. (0001851657) (Filer)
Robert W. Baird initiated coverage of Vaxxinity with a rating of Outperform and set a new price target of $7.00
Evercore ISI initiated coverage of Vaxxinity with a rating of In-line
Jefferies resumed coverage of Vaxxinity with a rating of Buy and set a new price target of $18.00
Jefferies initiated coverage of Vaxxinity with a rating of Buy and set a new price target of $18.00
B of A Securities initiated coverage of Vaxxinity with a rating of Buy and set a new price target of $21.00
SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G - Vaxxinity, Inc. (0001851657) (Subject)
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. Data demonstrates target engagement and immunogenicity of the active immunotherapy UB-312 targeting pathological alpha-synuclein. CAPE CANAVERAL, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (OTC:VAXX), a U.S. company pioneering the development of a new class of medicines known as AIMs (active immunotherapy medicines), announced today that Nature Medicine has published groundbreaking exploratory data from the Company's Phase 1 clinical trial of UB-312 in patients with Parkinson's disease (PD). The succes
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. ("Vaxxinity", "we", "us" or the "Company") (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu. To Shareholders of Vaxxinity, Inc.: Earlier today, we announced that we are delisting and deregistering our shares. A few weeks from now, we will no longer be publicly traded on the NASDAQ exchange. It is important to share why we made this decision to "go dark" and why we believe it is in the best interests of the company and our shareholders over
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. ("Vaxxinity", "we", "us" or the "Company") (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market ("Nasdaq") and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and suspend its reporting obligations under Section 15(d) of the Exchange Act. On February 9, 2024, the Company received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC indicating that the Company was no longer
CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson's disease at the Annual Academy of Neurology (AAN) 2024 Annual Meeting, taking place April 13-18, 2024 virtually and in Denver, Colorado. Presentation details are as follows:Oral PresentationSession: ES2 - Emerging ScienceTitle: Evidence of Target Engagement in a Phase 1 Clinical Trial of UB-312 in Parkinson's DiseasePresenter: Jean-Cosme Dodart, Ph.D., CSO at VaxxinityDate & Time: April 16, 2024 at 5:54 pm MT The AAN Annual Meeting is the la
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. "2024 will prove to be a critical year for Vaxxinity as we refocus our efforts on our neurodegeneration programs and move closer to obtaining our company's first approval," said Mei Mei Hu, CEO of Vaxxinity. "Just this month, we presented exploratory biomarker data from our Phase 1 trial of UB-312 in Parkinson's patients: a first of its kind demonstrating target engagement of toxic alpha-sy
LISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, announced positive clinical data from its UB-312 program in Parkinson's disease (PD) presented by Jean-Cosme Dodart, PhD, SVP of Research at Vaxxinity in an oral session at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Disease, held virtually and in Lisbon, Portugal from March 5 to March 9, 2024. UB-312 is the first active immunotherapy candidate to show reduction of pathological alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of PD patients. UB-312 is designed to target aggregated forms of aSyn, the toxic
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing, with topline results expected mid-2024. CAPE CANAVERAL, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results, which support the continued clinical development of VXX-401 as a candidat
CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson's disease and preclinical data from its anti-tau program in Alzheimer's disease at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD 2024), taking place March 5-9, 2024 virtually and in Lisbon, Portugal. Presentation details are as follows: Oral PresentationTitle: Evidence of Target Engagement in a Phase 1 Clinical Trial of UB-312 in Parkinson's DiseasePresenter: Jean-Cosme Dodart, Ph.D., SV
CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration with the University of Florida's (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases. The research, funded by a grant from the state of Florida, aims to further the development of Vaxxinity's active immunotherapies to prevent and mitigate neurodegenerative diseases, having the potential to change the future of treatment by offering people an affordable and accessible therapeutic option. "O
CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research. The research, funded by a grant from the State of Florida, aims to further the development of Vaxxinity's active immunotherapies to prevent and mitigate muscle and bone wasting, which are well known health challenges related to long-term spaceflight, and which share biological mechanisms implicated in highly prevalent age-related diseases. "If humanity is to become a spacefaring species, solving fundamental problems rela
Appointment adds Dr. Powchik's experience in the development of marketed immunotherapeutics to Vaxxinity's leadership team CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity's leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023. He will remain as a member of Vaxxinity's board of directors. Peter will oversee the overall scientific direction of Vaxxinity's platform and programs, and lead the development efforts at Vaxxinity. "Get ready for the next wave of innovative drug science at V
Appointment of new directors bring diversity, balance and relevant industry expertise to Vaxxinity Establishment of Frontier Exploration Laboratories ("VaxxLabs") in Cape Canaveral, Fla., as corporate headquarters CAPE CANAVERAL, Fla., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced new appointments to the Board of Directors and the relocation of its corporate headquarters to Cape Canaveral, Fla. "Today's announcements reflect the strength of Vaxxinity's science and people and further equip us to achieve key research and commercial milestones as we prepare to launch our fir
DALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines for chronic diseases, today announced that Peter Powchik, M.D. is joining its Board of Directors and will be retiring as Vaxxinity's Executive Vice President, Research & Development. This transition will be effective March 31, 2022 and will increase the size of the Board to seven. "Peter is a rockstar of drug development who has contributed to the approval of over half a dozen new drugs that help patients to this day. We are fortunate to have him joining our Board where we may continue to leverage his considerable expertise to dev
DALLAS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the appointment of Jason Pesile, MBA, CPA, as Senior Vice President, Finance & Accounting. The Company also announced today the appointment of George Hornig, Chairman of Xometry, to its Board of Directors. Mr. Hornig will be the new independent director to chair the Audit Committee, with current Board members Greg Blatt and Peter Diamandis moving to chair the Compensation Committee and Nominating and Governance Committee, respectively. "We are thrilled to welcome Jason to our management team and George to the Vaxx